ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

KZIA Kazia Therapeutics Ltd

0,3887
0,01875 (5,07%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Kazia Therapeutics Ltd KZIA NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
0,01875 5,07% 0,3887 06:00:15
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,3646 0,357 0,389 0,37 0,36995
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
21.3.202413:52PRNUSKazia Therapeutics licenses paxalisib to Sovargen for..
13.3.202413:00PRNUSKazia announces presentation of new data at AACR Annual..
21.2.202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
21.2.202415:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21.2.202413:30PRNUSKazia Therapeutics Reports Early Conclusion of Clinical..
14.2.202421:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13.2.202400:35EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.2.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05.2.202422:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18.1.202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18.1.202413:30PRNUSKAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
12.1.202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.12.202323:26EDGAR2Form F-3 - Registration statement by foreign private issuers
06.12.202314:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.12.202300:02PRNUSKazia Therapeutics Announces Closing of $2 Million..
04.12.202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01.12.202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.12.202314:00PRNUSKazia Therapeutics Announces $2 Million Registered Direct..
29.11.202322:19EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.11.202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.11.202313:01PRNUSKAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE..
21.11.202313:30PRNUSKAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS..
20.11.202322:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.11.202322:30PRNUSKAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
15.11.202315:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15.11.202314:30PRNUSKAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY..
10.11.202313:01PRNUSKAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS..
01.11.202321:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01.11.202312:01PRNUSKAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING..
26.10.202313:56EDGAR2Form 20-F - Annual and transition report of foreign private..
23.10.202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23.10.202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM..
13.10.202322:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.10.202313:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.10.202313:01PRNUSKazia announces voluntary delisting from ASX
10.10.202321:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.10.202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.10.202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING..
29.9.202313:01PRNUSKAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING..
29.9.202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.9.202313:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11.8.202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.7.202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.7.202313:00PRNUSKAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA..
08.6.202313:00PRNUSKAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO..
25.5.202313:01PRNUSKAZIA CEO, DR. JOHN FRIEND TO PARTICIPATE IN WHITE HOUSE..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock